In this paper, we introduce a trispecific TCE which targets CD38 on MM cells and CD3 on T-cells, similarly to bispecific T-cell engagers, but includes a CD28 arm which can bind to both tumor and T-cell antigens as well9. This evidence concerns the gene CD28 and neoplasm.